纳米颗粒在妊娠中的应用:生殖治疗的新前沿
本综述总结了纳米医学在生殖医学和产科中的现状,涵盖安全性、潜在应用、未来方向及转化障碍。临床前研究显示纳米颗粒靶向治疗可用于子宫肌瘤、子宫内膜异位症、异位妊娠、妊娠滋养细胞疾病及子痫前期等,并可能减少胎儿或母亲的不良暴露。
要点
- 纳米递送系统可靶向递送治疗剂,最大化疗效并减少脱靶效应。
- 生殖医学中纳米治疗有望用于子宫肌瘤、子宫内膜异位症和基因操作。
- 产科中纳米递送可稳定递送沉默RNA/miRNA抑制剂至胎盘,或限制致畸药物至母体。
核心结论
- 纳米颗粒靶向治疗在生殖领域有潜力实现安全定向治疗,管理影响女性健康和生殖能力的疾病及妊娠并发症。
研究设计与样本
- 综述,检索PubMed和Web of Science数据库至2020年2月,纳入英文研究,关注纳米颗粒技术在生育、基因治疗、早期妊娠并发症和产科并发症中的应用及安全性。
主要发现
- 非激素靶向纳米颗粒治疗子宫肌瘤和子宫内膜异位症可能提供保留生育力的药物治疗。
- 纳米技术递送干预为哺乳动物配子的基因操作和递送提供机会。
- 靶向细胞毒治疗早期妊娠组织为管理异位妊娠和妊娠滋养细胞疾病提供替代方法。
- 纳米治疗递送可稳定递送沉默RNA和微小RNA抑制剂至胎盘以调控基因表达,为子痫前期和胎儿生长受限提供新遗传治疗。
- 限制致畸药物(如华法林)至母体隔室可降低胎儿风险;靶向递送药物至胎儿(如治疗胎儿心律失常)可最小化母亲副作用。
临床怎么用
- 纳米递送系统可能为生殖医学和产科提供靶向干预策略,治疗疾病根源并减少对母亲和胎儿的长期后果。
局限性
- 综述未报告具体研究数量、样本量或安全性数据,转化障碍包括对配子、胚胎或胎儿损害的担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nanotechnology involves the engineering of structures on a molecular level. Nanomedicine and nano-delivery systems have been designed to deliver therapeutic agents to a target site or organ in a controlled manner, maximizing efficacy while minimizing off-target effects of the therapeutic agent administered. In both reproductive medicine and obstetrics, developing innovative therapeutics is often tempered by fears of damage to the gamete, embryo or developing foetus or of negatively impacting a woman's reproductive potential. Thus, nanomedicine delivery systems may provide alternative targeted intervention strategies, treating the source of the disease and minimizing long-term consequences for the mother and/or her foetus. OBJECTIVE AND RATIONALE: This review summarizes the current state of nanomedicine technology in reproductive medicine and obstetrics, including safety, potential applications, future directions and the hurdles for translation. SEARCH METHODS: A comprehensive electronic literature search of PubMed and Web of Science databases was performed to identify studies published in English up until February 2020. Relevant keywords were used to obtain information regarding use of nanoparticle technology in fertility and gene therapy, early pregnancy complications (ectopic pregnancy and gestational trophoblastic disease) and obstetric complications (preeclampsia, foetal growth restriction, preterm birth and gestational diabetes) and for selective treatment of the mother or foetus. Safety of specific nanoparticles to the gamete, embryo and foetus was also investigated. OUTCOMES: Pre-clinical research in the development of nanoparticle therapeutic delivery is being undertaken in many fields of reproductive medicine. Non-hormonal-targeted nanoparticle therapy for fibroids and endometriosis may provide fertility-sparing medical management. Delivery of interventions via nanotechnology provides opportunities for gene manipulation and delivery in mammalian gametes. Targeting cytotoxic treatments to early pregnancy tissue provides an alternative approach to manage ectopic pregnancies and gestational trophoblastic disease. In pregnancy, nanotherapeutic delivery offers options to stably deliver silencing RNA and microRNA inhibitors to the placenta to regulate gene expression, opening doors to novel genetic treatments for preeclampsia and foetal growth restriction. Restricting delivery of teratogenic drugs to the maternal compartment (such as warfarin) may reduce risks to the foetus. Alternatively, targeted delivery of drugs to the foetus (such as those to treat foetal arrythmias) may minimize side effects for the mother. WIDER IMPLICATIONS: We expect that further development of targeted therapies using nanoparticles in a reproductive setting has promise to eventually allow safe and directed treatments for conditions impacting the health and reproductive capacity of women and for the management of pregnancy and serious pregnancy complications.
引用
- Pritchard N, Kaitu'u-Lino T, Harris L, et al. Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. Hum Reprod Update. 2021. PMID: 33279994. doi:10.1093/humupd/dmaa049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。